Last reviewed · How we verify
NCT05999799: AtDventure
A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis
Phase 2 trial testing GSK1070806 in Dermatitis, Atopic in 161 participants. Terminated before completion.
23 July 2025
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 161 |
| Start date | 16 November 2023 |
| Primary completion | 23 July 2025 |
| Estimated completion | 23 July 2025 |
| Sites | 89 locations across France, Italy, Japan, Panama, Greece, Germany, Poland, Mexico |
Drugs / interventions tested
- GSK1070806 — full drug profile →
- Placebo
Conditions studied
- Dermatitis, Atopic — all drugs for Dermatitis, Atopic →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
Adults 18 to 75, any sex, with Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
IL-18 and IL-18BP: A Unique Dyad in Health and Disease.
Novick D. · · 2024 · cited 17× · PMID 39769266 · DOI 10.3390/ijms252413505 -
IL-18 biology in severe asthma.
Thawanaphong S, Nair A, Volfson E, Nair P, et al · · 2024 · cited 9× · PMID 39554494 · DOI 10.3389/fmed.2024.1486780 -
Very Early-Onset IBD-Associated IL-18opathy Treated with an Anti-IL-18 Antibody.
Guha A, Diaz-Pino R, Fagbemi A, Hughes SM, et al · · 2024 · cited 2× · PMID 39458007 · DOI 10.3390/jcm13206058 -
Inflammasome pathways in atopic dermatitis: insights into inflammatory mechanisms and therapeutic targets.
Ramos YÁL, Pietrobon AJ, Teixeira FME, Aoki V, et al · · 2025 · PMID 40555102 · DOI 10.1016/j.abd.2025.501136
Verify or expand the search:
- PubMed search for NCT05999799
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of GSK1070806
Trials testing the same drug.
- NCT06447506 — Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. · Phase 2 · terminated
- NCT05590338 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intr · Phase 1 · completed
- NCT04975438 — Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis · Phase 1 · completed
- NCT03681067 — A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease · Phase 1, PHASE2 · completed
- NCT03522662 — Anti IL-18 (GSK1070806) in Behcet's Disease · Phase 2 · unknown
Other recruiting trials for Dermatitis, Atopic
Currently open trials in the same condition.
- NCT07230860 — A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
- NCT06899204 — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate · recruiting
- NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
- NCT06881251 — A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) · Phase 2 · active not recruiting
- NCT06554847 — Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis · Phase 3 · active not recruiting
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05999799 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05999799.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing